HTG Molecular Diagnostics Inc. [HTGM] gain 23.06% so far this year. What now?

HTG Molecular Diagnostics Inc. [NASDAQ: HTGM] stock went on an upward path that rose over 3.15% on Friday, amounting to a one-week price increase of more than 47.45%. The company report on January 9, 2023 that HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


HTG Therapeutics, the company’s drug discovery business unit, has been actively using its transcriptome-informed approach to drug discovery to design and further refine small-molecule chemical libraries throughout 2022. This drug discovery platform is an integrated transcriptomic machine learning chemistry-based drug discovery engine that is expected to help overcome the traditional challenges of selecting and designing drug candidates by rendering a higher potential for success in development. The goal of this transcriptome-informed approach is to enable the selection and characterization of de-risked candidate molecules across selected therapeutic targets of interest leading to potential business development and licensing opportunities in various therapeutic areas.

Over the last 12 months, HTGM stock dropped by -89.87%. The one-year HTG Molecular Diagnostics Inc. stock forecast points to a potential upside of 50.9. The average equity rating for HTGM stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $10.51 million, with 0.92 million shares outstanding and 0.73 million shares in the current float. Compared to the average trading volume of 1.16M shares, HTGM stock reached a trading volume of 17237190 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on HTG Molecular Diagnostics Inc. [HTGM]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HTGM shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HTGM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for HTG Molecular Diagnostics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 11, 2020. The new note on the price target was released on March 26, 2020, representing the official price target for HTG Molecular Diagnostics Inc. stock. Previously, the target price had yet another raise from $4.50 to $6, while Rodman & Renshaw kept a Buy rating on HTGM stock.

The Average True Range (ATR) for HTG Molecular Diagnostics Inc. is set at 1.65, with the Price to Sales ratio for HTGM stock in the period of the last 12 months amounting to 1.55. The Price to Book ratio for the last quarter was 3.75, with the Price to Cash per share for the same quarter was set at 3.04.

HTGM Stock Performance Analysis:

HTG Molecular Diagnostics Inc. [HTGM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 47.45. With this latest performance, HTGM shares dropped by -43.33% in over the last four-week period, additionally sinking by -78.35% over the last 6 months – not to mention a drop of -89.87% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTGM stock in for the last two-week period is set at 50.72, with the RSI for the last a single of trading hit 54.79, and the three-weeks RSI is set at 49.24 for HTG Molecular Diagnostics Inc. [HTGM]. The present Moving Average for the last 50 days of trading for this stock 5.40, while it was recorded at 3.99 for the last single week of trading, and 9.07 for the last 200 days.

Insight into HTG Molecular Diagnostics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and HTG Molecular Diagnostics Inc. [HTGM] shares currently have an operating margin of -205.48 and a Gross Margin at +54.02. HTG Molecular Diagnostics Inc.’s Net Margin is presently recorded at -192.49.

Return on Equity for this stock declined to -137.80, with Return on Assets sitting at -52.23.

HTG Molecular Diagnostics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.60.

HTG Molecular Diagnostics Inc. [HTGM] Insider Position Details

There are presently around $0 million, or 4.30% of HTGM stock, in the hands of institutional investors. The top three institutional holders of HTGM stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 7,200, which is approximately -43.908% of the company’s market cap and around 10.90% of the total institutional ownership; BLACKROCK INC., holding 6,182 shares of the stock with an approximate value of $30000.0 in HTGM stocks shares; and VIRTU FINANCIAL LLC, currently with $30000.0 in HTGM stock with ownership of nearly 451.828% of the company’s market capitalization.

Positions in HTG Molecular Diagnostics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 4 institutional holders increased their position in HTG Molecular Diagnostics Inc. [NASDAQ:HTGM] by around 5,089 shares. Additionally, 11 investors decreased positions by around 16,917 shares, while 7 investors held positions by with 16,661 shares. The mentioned changes placed institutional holdings at 38,667 shares, according to the latest SEC report filing. HTGM stock had 1 new institutional investments in for a total of 8 shares, while 4 institutional investors sold positions of 1,730 shares during the same period.


Please enter your comment!
Please enter your name here